APC resistance: biological basis and acquired influences

被引:86
作者
Castoldi, E. [1 ]
Rosing, J. [1 ]
机构
[1] Maastricht Univ, Dept Biochem, NL-6200 MD Maastricht, Netherlands
关键词
APC resistance; FVLeiden; oral contraceptives; thrombosis; ACTIVATED-PROTEIN-C; COAGULATION-FACTOR VA; 3RD-GENERATION ORAL-CONTRACEPTIVES; FACTOR PATHWAY INHIBITOR; PEPTIDE-BOND CLEAVAGES; TISSUE FACTOR PATHWAY; HUMAN-FACTOR-VIII; VENOUS THROMBOSIS; LEIDEN MUTATION; ANTICOAGULANT ACTIVITY;
D O I
10.1111/j.1538-7836.2009.03711.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Proteolytic inactivation of factors Va (FVa) and VIIIa (FVIIIa) by activated protein C (APC) and its cofactors protein S and factor V (FV) is a key process in the physiological down-regulation of blood coagulation. Functional abnormalities of this pathway, which manifest themselves in vitro as a poor anticoagulant response of plasma to added APC (APC resistance), are prevalent in the general population and are associated with an increased risk of venous thrombosis. APC resistance was originally discovered in thrombophilic families and later shown to be associated with the common FV Arg506Gln (FVLeiden) mutation, which abolishes one of the APC-cleavage sites in FV. Although FVLeiden is the major cause of hereditary APC resistance, it is becoming increasingly clear that several other genetic and acquired conditions contribute to APC resistance and thereby increase the risk of venous thrombosis. This paper reviews the multifactorial etiology of APC resistance and discusses its clinical implications.
引用
收藏
页码:445 / 453
页数:9
相关论文
共 100 条
[41]   CHARACTERIZATION OF THE MOLECULAR DEFECT IN FACTOR V-R506Q [J].
KALAFATIS, M ;
BERTINA, RM ;
RAND, MD ;
MANN, KG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (08) :4053-4057
[42]  
KALAFATIS M, 1994, J BIOL CHEM, V269, P31869
[43]   Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation:: a randomized [J].
Kemmeren, JM ;
Algra, A ;
Meijers, JCM ;
Tans, G ;
Bouma, BN ;
Curvers, J ;
Rosing, J ;
Grobbee, DE .
BLOOD, 2004, 103 (03) :927-933
[44]   The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model [J].
Kolfschoten, MV ;
Dirven, RJ ;
Tans, G ;
Rosing, J ;
Vos, HL ;
Bertina, RM .
BLOOD COAGULATION & FIBRINOLYSIS, 2002, 13 (03) :207-215
[45]   The influence of factor VIII on measurement of activated protein C resistance [J].
Laffan, MA ;
Manning, R .
BLOOD COAGULATION & FIBRINOLYSIS, 1996, 7 (08) :761-765
[46]   Factor V Cambridge mutation and activated protein C resistance assays [J].
Le Cam-Duchez, V ;
Chrétien, MH ;
Saugier-Veber, P ;
Borg, JY .
THROMBOSIS AND HAEMOSTASIS, 2006, 95 (03) :581-583
[47]   Clinical significance of Arg306 mutations of factor V gene [J].
Liang, R ;
Lee, CK ;
Wat, MS ;
Kwong, YL ;
Lam, CK ;
Liu, HW .
BLOOD, 1998, 92 (07) :2599-2600
[48]   Comparison of activated protein C protein S-mediated inactivation of human factor VIII and factor V [J].
Lu, DS ;
Kalafatis, M ;
Mann, KG ;
Long, GL .
BLOOD, 1996, 87 (11) :4708-4717
[49]  
Lunghi B, 1996, THROMB HAEMOSTASIS, V75, P45
[50]   Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera [J].
Marchetti, Marina ;
Castoldi, Elisabetta ;
Spronk, Henri M. H. ;
van Oerle, Rene ;
Balducci, Donatella ;
Barbui, Tiziano ;
Rosing, Jan ;
ten Cate, Hugo ;
Falanga, Anna .
BLOOD, 2008, 112 (10) :4061-4068